Rebody Health Tirzepatide Review: Availability & Care Terms

Rebody Health's current public pages do not establish a named tirzepatide plan, price or formulation. Its October 25 catalog displayed 20 treatments, including sermorelin, PT-141 and NAD+ products, while a focused site search for “tirzepatide” returned zero results. This limited public-page check does not establish that the business has closed or that no tirzepatide pathway exists elsewhere.^3,4

For someone specifically seeking tirzepatide, the practical issue is getting a current named offer before making a payment decision. Neither a general peptide promotion nor prices for other catalog treatments establishes the price of tirzepatide. Current injectable, oral and branded tirzepatide availability remains unconfirmed in the reviewed public material.^3,4,5

What the public service documents establish

The Terms, updated October 20, 2026, identify Compound Technologies, Inc. as operator. Selecting or purchasing treatment starts a care request; it does not guarantee a prescription. A provider may approve, request further information, recommend another option or decline. Rebody is not itself a pharmacy, and the Terms describe dispensing by independent licensed U.S. pharmacies or authorized partners without identifying a tirzepatide dispenser.⁶

The homepage describes clinician-reviewed prescription peptide care and displays a LegitScript certification claim. That is an attributed website claim, not an independent certification or license verification in this review. Advisory-board biographies also do not establish the identity or credentials of the clinician assigned to a particular care request.⁵

The Terms list all 50 states and the District of Columbia under general jurisdictions served, excluding territories and countries outside the United States. They also require service to be legally available where the patient is located. That platform-level list is not confirmation that a particular tirzepatide product is available in every listed jurisdiction.⁶

Billing: included consultation is not an extra medication quote

Rebody's general care plans include a $20 consultation fee for the licensed-provider evaluation. It may appear as a separate evaluation, consultation or visit line in checkout or records. The Terms do not establish that $20 is an additional fee on top of a currently confirmed tirzepatide price, because that named price is not established here.⁶

Subscription authorization covers the amount due today and recurring payments at the renewal amount and interval shown in checkout. An introductory promotion applies only for its disclosed period. The public homepage describes payment today and shipment if prescribed, so do not assume payment waits until approval. Obtain the total first payment, subsequent amount, billing interval and supplied quantity for the actual selected treatment.^5,6

To stop future care-plan charges, the Terms say to cancel before the next billing date through the Rebody account or by emailing support. Cancellation ends renewals; the refund rules for an order already in progress are separate. A skincare subscription has its own email-based management route, which should not be confused with a prescription care plan.⁶

General refund protections have defined stages

The June 18, 2026 Refund Policy promises a full refund to the original payment method when the provider declines the requested treatment. Its evaluation-line explanation says the amount paid for the declined care request is refunded; it does not exclude the included provider-evaluation line. Cancellation before provider review also receives a full refund.⁷

Once prescription medication has been dispensed or shipped, it cannot be returned or refunded under the published policy. Canceling a recurring plan stops future charges but does not reverse an already dispensed or shipped order. Report a damaged or incorrect shipment within seven days, with photos; the stated remedy is a no-cost replacement if confirmed.⁷

These are general care-request terms. They do not establish current tirzepatide availability, a particular prescription, or a guaranteed result. If offered tirzepatide, ask which current policy applies to that exact request before authorizing payment.

Medication evidence is a separate question

Compounded tirzepatide is not an FDA-approved finished product. Public descriptions of unrelated peptide injections or sublingual products do not demonstrate equivalent tirzepatide formulations or clinical results. Our guide explains compounded tirzepatide's legal status.

If a clinician does recommend tirzepatide, discuss Zepbound side effects, gallbladder risk and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

Comparing a confirmed offer

For other published provider descriptions, see Luvo Health, PreventiveMD, RestorLife Med, Revel Health, Roen Rx and Shape Vantage. Compare each one's own current product and payment conditions; these links do not establish equivalent availability, pharmacy standards or refund rights. Our provider comparison covers the broader field.